All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Real-World Analysis Reveals Gaps in HRR Testing and PARP Inhibitor Treatment in mCRPC

February 22nd 2025

Most patients with mCRPC included in a real-world study did not undergo HRR testing at the time of diagnosis.

Strategic and Safe Lorlatinib Use Is Key to Optimal ALK+ NSCLC Management

February 21st 2025

D. Ross Camidge, MD, PhD, discusses ways that ALK-positive NSCLC management has changed based on 5-year follow-up data with lorlatinib in the CROWN trial.

TERZO Trial Seeks to Validate Duvelisib as an Effective Targeted Treatment in TFH Nodal T-Cell Lymphoma

February 21st 2025

Christopher P. Fox, MBChB(Hons), PhD, FRCP, FRCPath, discusses the ongoing evaluation of duvelisib in nodal T-cell lymphoma.

Mevrometostat Plus Enzalutamide Improves rPFS vs Enzalutamide in Metastatic CRPC

February 21st 2025

Pivotal phase 3 trials are ongoing following data from a phase 1 study showing that adding mevrometostat to enzalutamide was safe and efficacious.

Kimberly Stegmaier Named as Pediatric Oncology Chair at Dana-Farber

February 21st 2025

Kimberly Stegmaier, MD, was recently named Chair of Pediatric Oncology at Dana-Farber Cancer Institute.

HyperVIEW X-Ray System Receives FDA Breakthrough Device Designation for Breast Cancer Imaging

February 21st 2025

The HyperVIEW X-ray system has received breakthrough device designation from the FDA for contrast-enhanced imaging for diagnosis of breast cancer.

RZ-001 Earns FDA Fast Track Designation in HCC

February 21st 2025

RZ-001 has received FDA fast track designation for the treatment of patients with hepatocellular carcinoma.

Odronextamab Shows Efficacy, Safety in R/R DLBCL After Progression Post–CAR T-Cell Therapy

February 21st 2025

Odronextamab produced durable responses in relapsed/refractory diffuse large B-cell lymphoma after disease progression following CAR T-cell therapy.

Pan-Tumor Approvals Stress the Need for Harmonized Testing and Reporting Strategies

February 21st 2025

Funda Meric-Bernstam, MD, highlights considerations with pan-tumor approvals and where testing and reporting should be improved for clarity/ease.

Frontline Therapy Selection in HCC Hinges on Bleeding Risk and Patient-Specific Factors

February 21st 2025

Mohammed Najeeb Al Hallak, MD, MS, discusses patient-specific factors to consider during the selection of frontline systemic therapy for HCC.

FDA Grants Fast Track Status to SIGX1094 for Diffuse Gastric Cancer

February 20th 2025

SIGX1094 received fast track designation from the FDA for diffuse gastric cancer.

Key HCC Trial Data Establish the Role of Later-Line Cabozantinib and Raise Further Frontline Questions

February 20th 2025

Gentry King, MD, discusses positive and negative outcomes following the phase 3 CELESTIAL and COSMIC-312 trials in patients with hepatocellular carcinoma.

Epcoritamab Elicits Durable CR Rates, Increases MRD Negativity in Relapsed/Refractory DLBCL

February 20th 2025

Julie M. Vose, MD, MBA, discusses the 3-year follow-up data with epcoritamab in patients with relapsed/refractory diffuse large B-cell lymphoma.

Learning to Dance

February 20th 2025

Networking is an underutilized skill that requires practice but can have a high impact on shaping your career path.

UT MD Anderson and Texas Children’s Hospital Announce Joint Venture to End Childhood Cancer

February 20th 2025

The University of Texas MD Anderson Cancer Center and Texas Children’s Hospital have announced a collaboration dedicated to pediatric cancer care.

Epcoritamab Gains Japanese Approval for R/R Follicular Lymphoma

February 20th 2025

The Ministry of Health, Labour, and Welfare in Japan has approved epcoritamab for relapsed or refractory follicular lymphoma.

Tambiciclib Plus Zanubrutinib Delivers Responses in R/R DLBCL

February 20th 2025

Tambiciclib plus zanubrutinib generated responses in patients with relapsed/refractory diffuse large B-cell lymphoma.

67Cu-SAR-bisPSMA Earns FDA Fast Track Designation for PSMA+ mCRPC

February 20th 2025

The FDA granted fast track designation to 67Cu-SAR-bisPSMA for PSMA-positive metastatic castration-resistant prostate cancer.

FDA Grants Breakthrough Therapy Designation to Petosemtamab Plus Pembrolizumab for PD-L1+ HNSCC

February 20th 2025

Petosemtamab/pembrolizumab received FDA breakthrough therapy designation for PD-L1–positive recurrent/metastatic head and neck squamous cell carcinoma.

Critical Next Step in Thymoma/Thymic Carcinoma Field Involves Examining Immunotherapies

February 20th 2025

Rohan Maniar, MD, details considerations when treating patients with rare thymic epithelial tumors as well as notable ongoing research in the field.